Medication info

Lozacan Plus Pro Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 200800411 · Notified 2008.01.09

This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Treatment with separately titrated losartan potassium and hydrochlorothiazide in combination may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of loop diuretics rather than thiazide drugs is preferred in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be provided with this drug.
Child dose
Pediatric patients (under 18 years): Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Treatment with separately titrated losartan potassium and hydrochlorothiazide in combination may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of loop diuretics rather than thiazide drugs is preferred in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be provided with this drug.

Child dose

Pediatric patients (under 18 years): Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who may become pregnant should not use this medication, and those planning to become pregnant or who are pregnant must consult a physician. This medication should not be administered to patients with certain allergies, severely impaired kidney or liver function, or electrolyte imbalances. Caution is required for patients with extremely low blood pressure, problems with renal blood vessels, a history of hyperuricemia or gout, and elderly patients. Since this medication has a blood pressure-lowering effect, dizziness or drowsiness may occur upon initiation of treatment or with dosage changes, necessitating caution when driving or operating machinery. During treatment, blood electrolytes and kidney function should be monitored regularly to detect any abnormalities early, especially for hypokalemia and hyperkalemia. Additionally, this medication may cause sensitivity to sunlight, so prolonged exposure to ultraviolet light should be avoided, and any skin abnormalities should be reported to a physician immediately. Drug interactions may occur if used in conjunction with other antihypertensives, diuretics, or potassium supplements, therefore all medications being taken should be disclosed to the physician. In case of overdose, symptoms such as hypotension and tachycardia may occur; immediate emergency care is necessary, and since this medication is not removed by hemodialysis, specialized treatment is required. While taking this medication, adequate hydration and maintenance of electrolyte balance should be ensured, and if symptoms worsen or adverse reactions are suspected, medical consultation should be sought immediately.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Lumbago
  • Dizziness
Show 131 more
  • Cough
  • Sinusitis
  • Upper respiratory tract infection
  • Rash
  • Angioedema
  • Skin peeling
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina
  • Arrhythmia
  • Cerebrovascular accident
  • Hypotension
  • Myocardial infarction
  • Secondary atrioventricular block
  • Anorexia
  • Constipation
  • Toothache
  • Dry mouth
  • Indigestion
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Arthralgia
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle stiffness
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory loss
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Nervous hyperexcitability
  • Panic disorder
  • Paresthesia
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremor
  • Dizziness
  • Shortness of breath
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Dry skin
  • Petechiae
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Dysgeusia
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Frequent urination
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Spasm
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Hemolytic anemia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Fever
  • Pneumonia
  • Pulmonary edema
  • Hyperglycemia
  • Diabetes
  • Hyperuricemia
  • Muscle spasm
  • Restlessness
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Stevens-Johnson syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Temporary blurred vision
  • Xanthopsia
  • Acute myopia
  • Acute angle-closure glaucoma
  • Thrombocytopenia
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Dry cough
  • Erythema ab Igne
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light entry. Moreover, it is important to store it at room temperature, between 1 to 30 degrees Celsius, to maintain its efficacy.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.